| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3728 |
| Trial ID | NCT06220097 |
| Disease | B-Cell Acute Lymphoblastic Leukemia | B-Cell Lymphoma Refractory |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | bridging therapy |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Study on the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen in CD19-targeting CAR-T Therapies |
| Year | 2024 |
| Country | China |
| Company sponsor | Wuhan Union Hospital, China |
| Other ID(s) | bridging regimen of CD19CAR-T |
| Cohort 1 | |||||||||||
|
|||||||||||